Establishing method and application of asthma-like chronic obstructive pulmonary overlap airway inflammation mouse model

Abstract

The invention discloses an establishing method and application of an asthma-like chronic obstructive pulmonary overlap airway inflammation mouse model. The model is constructed by any one of the following modes: S1, smoking and aspergillus protease induced ACO-like model: enabling mice to inhale smoke of cigarettes every day from the 0th day; after smoking treatment is completed for 3-7 days, enabling an aspergillus protease solution to be dropwise added into the noses to sensitize the mice, wherein an ACO-like model is constructed; S2, preparing an ACO-like model induced by nano carbon blackparticles and aspergillus protease: intranasally dripping the nano carbon black particles into the anesthetized mice from the 0th day, wherein after the nano carbon black particles are treated for 2 weeks, an aspergillus protease solution is dropwise added into the noses to sensitize mice, and an ACO-like model is constructed. The constructed ACO-like model can simulate the characteristic that asthma chronic obstructive pulmonary overlap occurs in the later stage of diseases of patients with chronic obstructive pulmonary disease clinically, and an experimental animal model is provided for ACOmorbidity mechanism and drug treatment research.

Description

technical field [0001] The invention belongs to the field of medical biology research, and in particular relates to a method for establishing a mouse model of asthma-like COPD overlapping airway inflammation and its application. Background technique [0002] Asthma-COPD overlap (ACO) is a disease state clinically characterized by both asthma and chronic obstructive pulmonary disease (COPD), and the incidence rate in obstructive airway diseases is about 20% . Global Asthma Report [1] It is pointed out that compared with simple asthma or COPD, the lung function of ACO patients declines faster and the condition worsens more frequently, and has become one of the major diseases with high disability and mortality rates in the world. However, most clinical studies of asthma and COPD exclude patients with ACO features due to the heterogeneity and uncertainty of chronic airway inflammation and the lack of knowledge about ACO. Moreover, most of the current clinical research on ACO ...

AI Technical Summary

Problems solved by technology

However, neither OVA nor PPE is a natural pathogenic factor for asthma and emphysema/COPD, and the model has the following shortcomings: ①Although OVA is a classic method for asthma models, it must be stimulated by intranasal instillation of OVA in mice. The model can be successfully modeled by intraperitoneal injection of OVA sensitization, which is different from the pathogenesis of asthma patients who directly inhale air sensitizers; ②The pan-lobular emphysema model caused by acute alveolar injury caused by one-time instillation of elastase is also consistent with Inconsistent pathological changes of centrilobular emphysema induced by common long-term smoking stimulation in COPD patients

Therefore, the above modeling methods do not conform to the natural pathogenesis of ACO patients, resulting in the extremely limited application of the current ACO model

[0

Images